


Drug-Coated Balloon Angioplasty in Atherosclerosis Patients With Popliteal Artery Involvement Dohi et al. *J Endovasc Ther.* 2018;25(5).

Supplementary Figure 1. Estimates of primary patency after drug-coated balloon angioplasty according to lesion location. BK, below-knee artery; PA, popliteal artery; SFA, superficial femoral artery (SFA).



	Time, mo		
	0	6	12
Isolated PA			
at risk	33	18	7
%	100	90.5	77.6
SE	0	0.06	0.13
SFA + PA			
at risk	187	113	67
%	100	89.7	78.8
SE	0	0.03	0.04
PA + BK			
at risk	29	18	12
%	100	85.4	73.4
SE	0	0.08	0.10
SFA + PA + BK			
At risk	32	9	5
%	100	68.0	34.0
SE	0	0.12	0.13

Drug-Coated Balloon Angioplasty in Atherosclerosis Patients With Popliteal Artery Involvement

Dohi et al. *J Endovasc Ther.* 2018;25(5).

Supplementary Table 1. Patient, Lesion, and Procedure Characteristics According to Lesion Location.

	Isolated PA	SFA + PA	PA + BK	SFA + PA + BK	p
Patient characteristics	n=32	n=174	n=29	n=31	
Age, y	73 (66, 75)	70 (61, 78)	73 (64, 79)	74 (68, 80)	0.45
Men	18 (56)	114 (66)	21 (72)	13 (42)	<0.05
Smoking history	14 (44)	86 (49)	12 (41)	14 (45)	0.82
Hypertension	30 (94)	171 (98)	27 (93)	30 (97)	0.3
Dyslipidemia	19 (59)	131 (75)	18 (62)	25 (81)	0.11
Diabetes	13 (41)	78 (45)	16 (55)	15 (48)	0.68
Coronary artery disease	7 (22)	43 (25)	9 (31)	15 (48)	0.04
Cerebrovascular disease	4 (12)	13 (7)	4 (14)	3 (10)	0.62
Renal insufficiency ^b	7 (22)	30 (17)	8 (29)	10 (32)	0.18
Obesity	9 (28)	40 (23)	13 (46)	12 (39)	0.03
Rutherford category					<0.001
2	7 (22)	17 (10)	3 (10)	3 (10)	
3	14 (44)	102 (59)	11 (38)	8 (26)	
4	2 (6)	29 (17)	3 (10)	4 (13)	
5	9 (28)	24 (14)	12 (41)	13 (42)	
6	0 (0)	0 (0)	0 (0)	3 (10)	
CLI	11 (34)	53 (31)	15 (52)	20 (65)	0.001
Preprocedural ABI	0.54 (0.48, 0.68)	0.6 (0.47, 0.76)	0.78 (0.61, 0.83)	0.49 (0.39, 0.67)	0.44
Lesion characteristics	n=33	n=187	n=29	n=32	
Lesion length, mm	120 (80, 160)	320 (240, 400)	120 (80, 160)	245 (200, 408)	<0.001
Reference vessel diameter, mm	5.0 (4.5, 5.0)	5.0 (4.8, 5.3)	4.0 (3.5, 4.5)	4.4 (4.0, 4.8)	<0.001
Total occlusion	23 (70)	126 (67)	22 (76)	26 (81)	0.39

Calcification					0.08
None	25 (76)	115 (61)	14 (48)	13 (41)	
Mild	5 (15)	27 (14)	9 (31)	7 (22)	
Moderate	1 (3)	29 (16)	3 (10)	8 (25)	
Severe	2 (6)	16 (9)	3 (10)	4 (12)	
Below-knee runoff					<0.001
None	2 (6)	11 (6)	12 (43)	15 (47)	
1-vessel	10 (31)	66 (37)	6 (21)	14 (44)	
2-vessel	8 (25)	60 (34)	7 (25)	2 (6)	
3-vessel	12 (38)	40 (23)	3 (11)	1 (3)	
DCBs per lesion	1 (1, 2)	(3 (2, 4)	(2 (2, 3)	(3 (2, 3.25)	
Atherectomy/thrombectomy device	18 (55)	45 (24)	5 (17)	7 (22)	0.03
Bailout stenting (n=147)	8 (24)	113 (60)	7 (24)	19 (59)	<0.001
Reason for stent use					0.006
Flow-limiting dissection	2	63	0	10	
Persistent stenosis	6	50	7	9	
Spot stenting					
Type of stent					<0.001
Standard nitinol stent	4	34	3	14	
Interwoven nitinol stent	4	79	4	5	
Severe dissection after procedure	4 (12)	89 (48)	7 (24)	18 (56)	<0.001

Abbreviations: ABI, ankle-brachial index; BK, below-knee artery; CLI, critical limb ischemia; DCB, drug-coated balloon; PA, popliteal artery; SFA, superficial femoral artery.

^aContinuous data are presented as the median (interquartile range Q1, Q3); categorical data are given as the counts (percentage).

^bEstimated glomerular filtration rate <60 mL/min/1.73 m².

Drug-Coated Balloon Angioplasty in Atherosclerosis Patients With Popliteal Artery Involvement

Dohi et al. *J Endovasc Ther.* 2018;25(5).

Supplementary Table 2. Comparison of Representative DCB Studies.

Study Name (DCB Arm)	Lesions	RVD, mm ^a	Lesion Length, cm ^a	Total Occlusions ^b	Calcified Lesions ^b	PA Lesions ^b	Severe Dissection ^b	Primary Patency ^c	Binary Restenosis ^c	TLR ^c
FemPac 2008 ⁸	45	5.2	4.0	6 (13)	24 (53)	6 (13)	NA	NA	4/23 (17) ^d	6/45 (13) ^d
Thunder 2008 ⁹	48	5.0	7.5	13 (27)	24 (50)	15 (31)	NA	NA	NA	5/48 (10)
PACIFIER 2012 ¹⁰	41	4.9	7.0	10 (23)	28 (64)	NA	18/38 (47)	NA	NA	3/39 (8)
DEBATE-SFA 2013 ¹²	55	5.0	9.4	30 (56)	12 (22)	14 (26)	NA	NA	9/55 (17)	83
Micari 2013 ¹¹	114	5.2	7.6	34 (30)	19 (17)	11 (10)	NA	84	NA	7
LEVANT I 2014 ¹³	49	4.1	8.1	20 (41)	0	4 (8)	NA	30/45 (67)	NA	13/45 (29)
INPACT SFA 2015 ¹⁴	221	4.6	8.9	57 (26)	18 (8)	15 (7)	0	157/191 (82)	NA	6/207 (3)
LEVANT 2 2015 ¹⁵	316	4.8	6.3	65 (21)	33 (10)	31 (10)	8 (26)	172/264 (65)	NA	35/285 (12)
ILLUMINATE EU 2017 ¹⁶	254	5.0	7.2	48 (19)	32 (13)	27 (11)	NA	89	36/224 (16)	12/205 (6)
Current study	281	5.0	27.0	197 (70)	25 (9)	281 (100)	118 (42)	77	NA	84

Abbreviations: DCB, drug-coated balloon; NA, not available; RVD, reference vessel diameter; TLR, target lesion revascularization.

^aData are presented as the means.

^bData are given as the counts/sample (percentage).

^cData given as the Kaplan-Meier estimate or counts/sample (percentage) at 1 year.

^dTwo-year data.